Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Pancreatic Ductal Adenocarcinoma: early-phase trial registry
5 of 8 indexed Locally Advanced Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Locally Advanced Pancreatic Ductal Adenocarcinoma: 8 US clinical trials tracked, 5 recruiting.
Locally Advanced Pancreatic Ductal Adenocarcinoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is OHSU Knight Cancer Institute, running 2 of these trials.
Enrollment posture brief
Registry condition locally-advanced-pancreatic-ductal-adenocarcinoma
OPEN 5 | RECR 63% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Locally Advanced Pancreatic Ductal Adenocarcinoma lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Locally Advanced Pancreatic Ductal Adenocarcinoma research.
OHSU Knight Cancer Institute accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Locally Advanced Pancreatic Ductal Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Locally Advanced Pancreatic Ductal Adenocarcinoma research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
NCT04005690
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
University of California, San Francisco
NCT06600906
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT05688215
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Xerient Pharma
NCT07157033
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
NCT07089940
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Flemming Forsberg
NCT04821284
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
NCT04481204
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
University of Utah
NCT04106856
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Pancreatic Ductal Adenocarcinoma page
8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Locally Advanced Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- OHSU Knight Cancer Institute sponsors the most Locally Advanced Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See OHSU Knight Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Pancreatic Ductal Adenocarcinoma condition card totals 8 registered trials; most-linked intervention Fluorouracil; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.